MITF from control of pigmentation to melanoma risk
MITF from control of pigmentation to melanoma risk
批准号:
10828041
负责人:
DAVID E FISHER
金额:
$9.0万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-16 至 2025-02-28
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Human skin phototypes are routinely described in a gradient of 1 (redhaired) to 6 (dark constitutive pigment)
which correlates with UV sensitivity and risk of melanoma, Parallel to this gradient is the increase of nevi (moles)
from darker to lighter phototypes, a gradient which abruptly drops at phototype 1 (redhaired) where visible nevi
are unexpectedly rare, We hypothesized, and verified in murine models, that BRAFveooE_ induced nevi in
redhaired mice are "invisible" but actually significantly more abundant compared to genetically matched black
mice, They are clinically inapparent due to lack of dark eumelanin, but are easily identified via fluorescence
tagging, and associated with profoundly elevated spontaneous melanoma transformation and UVA-induced
melanoma risk in redhaired mice, This melanoma risk was traced to red pigment because "albino-redhaired"
mice lack all pigment and are protected from either spontaneous (previously published), UVA-induced, or
peroxide-induced melanoma, Spontaneous and UVA-induced "invisible" nevi and melanoma-genesis are
proposed for study in Aims 1 and 2 for NRASQ61
R pigment models, the 2"d most common human nevus and
melanoma oncogene, to complement our extensive unpublished data for BRAFveooE, Several small molecule
approaches will be tested to potentially mitigate pheomelanin-induced melanoma risk including induction of dark
eumelanin synthesis, One such example was already seen to "reveal" visible lesions in the "invisible" nevusbearing
redhaired mice, In addition, the fluorescent nevi, engineered into isogenic pigment backgrounds, will be
flow-sorted from skin and transcriptomically scrutinized to mechanistically dissect the pathways and genes
(including redox) that mediate the elevated melanoma risk among fair skinned individuals, Only a minority of
melanomas arise from pre-existing nevi, so we use our models to examine both nevi and overall melanoma risk,
We also discovered that the Parkinson's Disease therapy L-Dopa significantly elevates pheomelanin synthesis
in redheads, Separate from being a dopamine precursor, L-Dopa is coincidentally a chemical intermediate in
melanin biosynthesis, Parkinson's Disease and melanoma have long been associated with one another, but
lacking a mechanistic explanation, We observed that low dose L-Dopa significantly elevates melanoma risk in
BRAFveooE redhaired, but not in albino-red mouse models (which cannot make pheomelanin or eumelanin), Aim
3 will test L-Dopa's melanoma causality in NRAS061R redhaired models and whether topical skin darkening may
modify the enhanced melanoma risk already observed for BRAFveooE, Finally, Aim 4 will examine the hypothesis
that M ITF regulates expression of an anti-oxidant pathway which includes enzymes controlling regeneration of
reduced NADPH and glutathione-key factors buffering melanocyte oxidative stress, One such enzyme, the
mitochondrial enzyme NNT, was recently shown to modulate melanocyte redox and melanosome differentiation,
We will test evidence that NNT is a transcriptional target of M ITF and functionally scrutinize a newly identified
sequence variant in NNT, nominated by NCI collaborators as a candidate familial melanoma gene in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
-
批准号:10331800
-
项目类别:
-
资助金额:$36.61万
-
财政年份:2018
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:9753925
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:9376481
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:10245261
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:10570507
-
项目类别:
-
资助金额:$51.17万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Preclinical models and therapeutic strategies for treatment of giant congenital melanocytic nevi
-
批准号:9977915
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2017
-
负责人:DAVID E FISHER
-
依托单位:
Development of next-generation cancer functional diagnostics
-
批准号:8492572
-
项目类别:
-
资助金额:$22.71万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Administrative Core
-
批准号:8415143
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
-
批准号:10443720
-
项目类别:
-
资助金额:$33.26万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
-
批准号:9792731
-
项目类别:
-
资助金额:$151.67万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Administrative Core
-
批准号:10658866
-
项目类别:
-
资助金额:$11.43万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
-
批准号:8415137
-
项目类别:
-
资助金额:$146.1万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera
-
批准号:8415140
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
-
批准号:8842005
-
项目类别:
-
资助金额:$140.55万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
-
批准号:9257289
-
项目类别:
-
资助金额:$140.77万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
-
批准号:10443719
-
项目类别:
-
资助金额:$143.05万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Administrative Core
-
批准号:10443723
-
项目类别:
-
资助金额:$11.43万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
-
批准号:10227092
-
项目类别:
-
资助金额:$34.14万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
-
批准号:10658849
-
项目类别:
-
资助金额:$142.84万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
-
批准号:10227091
-
项目类别:
-
资助金额:$146.17万
-
财政年份:2013
-
负责人:DAVID E FISHER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
The Heterogenous Impact of Monetary Policy on Firms' Risk and Fundamentals
-
批准号:--
-
项目类别:外国学者研究基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:潘军
-
依托单位:
基于移动健康技术干预动脉粥样硬化性心血管疾病高危人群的随机对照现场试验:The ASCVD Risk Intervention Trial
-
批准号:81973152
-
项目类别:面上项目
-
资助金额:54.0万元
-
批准年份:2019
-
负责人:胡东生
-
依托单位:
基于时间序列间分位相依性(quantile dependence)的风险值(Value-at-Risk)预测模型研究
-
批准号:71903144
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2019
-
负责人:张申
-
依托单位:
RISK通路在胃泌素介导的心脏缺血再灌注损伤保护中的作用研究
-
批准号:81800239
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:符金娟
-
依托单位:
异氟烷基于TLR4/RISK/NF-κB调控糖尿病缺血性脑卒中后NLRP3炎症小体形成的机制研究
-
批准号:81771232
-
项目类别:面上项目
-
资助金额:54.0万元
-
批准年份:2017
-
负责人:张鸿飞
-
依托单位:
Notch1与RISK/SAFE/HIF-1α信号通路整合在I-postC保护中的作用及其机制
-
批准号:81260024
-
项目类别:地区科学基金项目
-
资助金额:50.0万元
-
批准年份:2012
-
负责人:刘季春
-
依托单位: